UY37621A - Arn terapéutico que codifica citoquinas - Google Patents

Arn terapéutico que codifica citoquinas

Info

Publication number
UY37621A
UY37621A UY0001037621A UY37621A UY37621A UY 37621 A UY37621 A UY 37621A UY 0001037621 A UY0001037621 A UY 0001037621A UY 37621 A UY37621 A UY 37621A UY 37621 A UY37621 A UY 37621A
Authority
UY
Uruguay
Prior art keywords
therapeutic
cytokins
codifies
arn
treatment
Prior art date
Application number
UY0001037621A
Other languages
English (en)
Inventor
Friederike Gieseke
Ugur Sahin
R Wagenaar Timothy
G Wiederschain Dmitri
Original Assignee
Sanofi Sa
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Biontech Rna Pharmaceuticals Gmbh filed Critical Sanofi Sa
Publication of UY37621A publication Critical patent/UY37621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta descripción se refiere al campo de los ARN terapéuticos que codifican citoquinas para el tratamiento de cánceres de tumor sólido.
UY0001037621A 2017-02-28 2018-02-27 Arn terapéutico que codifica citoquinas UY37621A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762464981P 2017-02-28 2017-02-28
EP17306089 2017-08-23
US201762597527P 2017-12-12 2017-12-12

Publications (1)

Publication Number Publication Date
UY37621A true UY37621A (es) 2018-09-28

Family

ID=61569463

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037621A UY37621A (es) 2017-02-28 2018-02-27 Arn terapéutico que codifica citoquinas

Country Status (21)

Country Link
US (3) US20200147176A1 (es)
EP (1) EP3589308A1 (es)
JP (4) JP6949131B2 (es)
KR (1) KR20190124750A (es)
CN (1) CN110337305A (es)
AU (1) AU2018229278A1 (es)
BR (1) BR112019017743A2 (es)
CA (1) CA3054733A1 (es)
CL (1) CL2019002461A1 (es)
CO (1) CO2019010355A2 (es)
CR (1) CR20190444A (es)
EC (1) ECSP19070336A (es)
IL (1) IL268894A (es)
MA (1) MA47680A (es)
MX (1) MX2019010269A (es)
PE (1) PE20200735A1 (es)
PH (1) PH12019501959A1 (es)
SG (1) SG11201907846VA (es)
TW (1) TW201842921A (es)
UY (1) UY37621A (es)
WO (1) WO2018160540A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110337305A (zh) 2017-02-28 2019-10-15 赛诺菲 治疗性rna
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
WO2019134048A1 (en) 2018-01-05 2019-07-11 Bell John C Modified orthopoxvirus vectors
WO2020041655A1 (en) * 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
CN113557060A (zh) * 2019-01-21 2021-10-26 赛诺菲 用于晚期实体瘤癌症的治疗性rna
JP2022518236A (ja) * 2019-01-21 2022-03-14 サノフイ 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体
US20210106527A1 (en) * 2019-10-09 2021-04-15 Translate Bio, Inc. Compositions, methods and uses of messenger rna
JP2021185136A (ja) 2020-04-22 2021-12-09 ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング コロナウイルスワクチン
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
EP4234567A1 (en) * 2020-10-20 2023-08-30 ST Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis
US20240166707A1 (en) 2021-01-08 2024-05-23 Strand Therapeutics Inc. Expression constructs and uses thereof
US20240102065A1 (en) * 2021-01-27 2024-03-28 CureVac SE Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN116829578A (zh) * 2021-10-08 2023-09-29 苏州艾博生物科技有限公司 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法
CN116179549A (zh) 2021-12-08 2023-05-30 南京吉迈生物技术有限公司 通过5’utr序列变体修饰基因转录和翻译效率
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN117327709A (zh) * 2022-06-24 2024-01-02 深圳瑞吉生物科技有限公司 用于实体肿瘤的治疗性mRNA及其应用
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024074211A1 (en) * 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074634A1 (en) * 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1442750B1 (en) 1997-11-20 2012-08-01 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
JP2003525222A (ja) 2000-01-20 2003-08-26 ウニベルジテート チューリッヒ インスティチュート フューア メディツィニーチェ ビロロギー Ｉｌ−１２をコードする核酸分子の腫瘍内投与
ES2164011B1 (es) 2000-02-25 2003-05-16 Inst Cientifico Tecnol Navarra Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003059381A2 (en) 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
DE10248141B4 (de) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP2439272A3 (en) 2005-05-09 2013-07-31 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
EP2578685B1 (en) 2005-08-23 2019-04-17 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
DK2201100T3 (en) 2007-09-14 2016-05-30 Univ Bruxelles IMPROVING THE T-CELL STIMULATING ABILITY OF HUMAN antigen presenting cells AND USE THEREOF IN THE VACCINATION
US20130108663A1 (en) 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
ES2537703T3 (es) 2008-01-31 2015-06-11 Curevac Gmbh Ácidos nucleicos que comprenden la fórmula (NuGlXmGnNv)a y sus derivados como agentes/adyuvantes inmunoestimuladores
US20110014241A1 (en) 2008-03-14 2011-01-20 The Board of Trustees of the Unversity Illinois Therapeutic Cancer Antigens
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
CA2734908A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP2013512690A (ja) 2009-12-07 2013-04-18 ザ トラスティース オブ ザ ユニバーシティ オブ ペンシルベニア 細胞を再プログラム化するための精製された修飾ｒｎａを含むｒｎａ調製物
KR102049161B1 (ko) 2010-03-23 2019-11-26 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CA3101783C (en) 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JP2015513913A (ja) * 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
ES2747997T3 (es) * 2012-10-24 2020-03-12 Novartis Ag Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa
ES2739913T3 (es) 2013-02-22 2020-02-04 Curevac Ag Combinación de vacunación e inhibición de la ruta PD-1
NZ751462A (en) 2013-03-14 2021-07-30 Shire Human Genetic Therapies Cftr mrna compositions and related methods and uses
LT2992017T (lt) 2013-05-02 2021-02-25 Anaptysbio, Inc. Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
ES2759910T3 (es) 2013-08-21 2020-05-12 Curevac Ag Composición y vacuna para el tratamiento del cáncer de pulmón
SG10201801433XA (en) 2013-08-21 2018-04-27 Curevac Ag Composition and vaccine for treating prostate cancer
WO2015035606A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
JP2017501712A (ja) 2013-12-18 2017-01-19 イントレキソン コーポレーション 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用
GB2517521B (en) 2013-12-19 2015-07-29 Anacail Ltd Drain decontamination system
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105031630A (zh) * 2014-04-28 2015-11-11 四川大学 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
EP3326641B1 (en) * 2015-04-22 2019-06-26 CureVac AG Rna containing composition for treatment of tumor diseases
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
EP3456346B1 (en) 2015-07-30 2021-07-07 MacroGenics, Inc. Pd-1 and lag-3 binding molecules and methods of use thereof
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2016305087B2 (en) 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
KR102434314B1 (ko) 2015-09-01 2022-08-19 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
EP4046655A1 (en) 2015-11-03 2022-08-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
KR20190039969A (ko) 2016-08-19 2019-04-16 큐어백 아게 암 치료법을 위한 rna
CN110337305A (zh) * 2017-02-28 2019-10-15 赛诺菲 治疗性rna
WO2020041655A1 (en) 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
JP2022518236A (ja) 2019-01-21 2022-03-14 サノフイ 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体
CN113557060A (zh) 2019-01-21 2021-10-26 赛诺菲 用于晚期实体瘤癌症的治疗性rna

Also Published As

Publication number Publication date
MX2019010269A (es) 2019-10-14
IL268894A (en) 2019-10-31
PH12019501959A1 (en) 2020-07-06
JP7461449B2 (ja) 2024-04-03
CN110337305A (zh) 2019-10-15
MA47680A (fr) 2020-01-08
SG11201907846VA (en) 2019-09-27
KR20190124750A (ko) 2019-11-05
CA3054733A1 (en) 2018-09-07
CO2019010355A2 (es) 2019-10-09
US20240173382A1 (en) 2024-05-30
US11865159B2 (en) 2024-01-09
CR20190444A (es) 2019-12-17
CL2019002461A1 (es) 2020-01-17
JP2024073650A (ja) 2024-05-29
BR112019017743A2 (pt) 2020-04-07
TW201842921A (zh) 2018-12-16
JP6949131B2 (ja) 2021-10-13
JP2021098735A (ja) 2021-07-01
JP2023030083A (ja) 2023-03-07
JP2020509016A (ja) 2020-03-26
US20210290730A1 (en) 2021-09-23
PE20200735A1 (es) 2020-07-23
ECSP19070336A (es) 2019-10-31
EP3589308A1 (en) 2020-01-08
US20200147176A1 (en) 2020-05-14
JP7201725B2 (ja) 2023-01-10
AU2018229278A1 (en) 2019-10-17
WO2018160540A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
UY37621A (es) Arn terapéutico que codifica citoquinas
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
UY37744A (es) Inhibidores de kras g12c y métodos para su uso
CL2017002909A1 (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras malignidades hematologicas cd38-positiva.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
CR20150316A (es) Compuestos y sus métodos de empleo
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2017003147A1 (es) Moduladores de receptor nuclear
ECSP22055515A (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231026